The thread listed many reports of success with this drug, as i said.
Name one. I've already directed you towards much evidence of the opposite conclusion.
Much evidence? Evidence posted online in news articles or forums when it comes to efficiacy of medications is irrelevant. Lets stick to peer-reviewed scientific evidence? Il try...
First of all I am NOT against HCQ, all I am saying is that people with political bias are rallying for it prematurely they may be correct but lets just wait for more evidence.
There are a number of in vitro (pre-clinical) studies which I will not cite but lets focus on the two big in- vivo papers on this
Chen et al.
This trial is well designed.
Methods:
30 patients positive for COVID total who were randomized to treatment group of HCQ 400mg for 5 days vs. standard supportive care in treatment group. Results were blinded. Primary outcome was NPP swab at day 7. Secondary outcomes were imaging findings, mortality and adverse events.
Results:
The intention-to-treat analysis revealed that the treatment group did not differ from the control group in the number of patients testing negative for COVID-19 on Day 7 (13 versus 14 patients), nor the duration of illness (all P>0.05).
Conclusion:
Inconclusive evidence.
Gautret et al
This study started off strong in its design but the authors failed to withhold their methodology, patients were moved from randomized groups and new therapies were added half way. Also the primary author is a very controvercial figure. Either way the results were promising
Methods:
open-label, non-randomised controlled trial with 36 patients diagnosed with COVID-19, of which six were asymptomatic, 22 had upper respiratory tract infection symptoms, and eight had lower respiratory tract infection symptoms
The twenty patients in the treatment group received HCQ 200mg three times a day for 10 days. Patients declining to take part in the study and not meeting the inclusion criteria were assigned to the control group and received usual care
outcome was polymerase chain reaction (PCR) of SARS-CoV-2 ribonucleic acid (RNA) on nasopharyngeal swabs on day 6.
Results:
Patients in the treatment group were significantly more likely to test negative for SARS-CoV-2 on Day 6 than control
Conclusions: This is preliminary results calling for more to be studied. The MAIN thing people fail to conclude that the authors themselves acknowledge is that their outcome was VIRAL load at day 6 which does not necessarily correlate to clinical findings but it is promising. The study according to the authors themselves was not statistically powered to make inferences but they stopped it early to raise awareness.
Since these two trials there are over 80 clinical trails now registered to study this drug, some are trickeling their findings but none has come out with a smoking gun in either direction. This drug isnt without risk though and untill more evidence comes people shouldn just blindingly start taking it because of what a politician has said based on a non-randomzied non controlled statistically under powered study looking at viral load on day 6.
Adverse events:
serious cutaneous adverse reactions
Fulminant hepatic failure
ventricular arrhythmias (especially when prescribed with azithromycin)
overdose is hazardous and difficult to treat.